There is growing excitement around AI in pharmacovigilance, but one career lesson is becoming clearer: in regulated environments, tool familiarity is not enough. Professionals who understand how to govern AI — how to define context of use, assess risk, document performance, support oversight, and manage lifecycle change — may become increasingly valuable. FDA’s January 2026 Good AI Practice principles support exactly that kind of skill profile.
The FDA principles repeatedly point toward capabilities that are as much organizational as they are technical. They emphasize multidisciplinary expertise, data governance and documentation, risk-based performance assessment, and clear essential information. In other words, the regulator is not signaling that success belongs only to coders or data scientists. It is signaling that safe and credible AI depends on professionals who can connect technical outputs to regulated processes and patient-protection goals.
That is where many PV professionals have an opportunity. People with backgrounds in case processing, aggregate reporting, quality, signal management, compliance, or medical review already understand the discipline of controlled work. If they add AI governance literacy — even without becoming technical developers — they may become especially useful in digital-transformation efforts. They can ask the questions that matter: What exactly is this tool doing? What is the context of use? What are the limits? Who reviews the output? How is performance monitored over time? Those questions are closely aligned with FDA’s framework.
This also reframes career development. Instead of thinking only in terms of “learning AI tools,” PV professionals may benefit more from learning how to evaluate AI within a regulated environment. That includes understanding governance models, documentation expectations, user oversight, validation thinking, and how to explain risks clearly to nontechnical stakeholders.
The professionals who stand out in 2026 and beyond may not be the ones using the flashiest tools. They may be the ones who can help organizations use those tools responsibly. In a regulated field like pharmacovigilance, that is a meaningful career differentiator.
Why this matters for PV professionals
AI is creating new opportunities in PV, but the strongest career advantage may come from understanding governance, oversight, and regulated deployment, not just prompt-writing or automation shortcuts. FDA’s current direction supports that view.
0 Comments